You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Profound Medical's device to treat uterine tumors approved by Chinese regulator
Identifying PPE Suppliers During the Pandemic
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021
Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective
Profound Medical Corp. said the China Food and Drug Administration approved its device Sonalleve for the noninvasive treatment of uterine fibroids.
Uterine fibroids are the most common noncancerous tumors of the female reproductive tract in women, according to the company.
The Canadian device-maker said the product enables more precise and incision-free removal of diseased tissue.
Profound Medical acquired the Sonalleve MR-HIFU business from Royal Philips in 2017.